Similar articles

• Cyclosporine-induced syngeneic graft-versus-host disease: recognition of self MHC class II antigens in vivo.

  Hess AD, Horwitz LR, Laulis MK. Hess AD, et al. Transplant Proc. 1993 Feb;25(1 Pt 2):1218-21. Transplant Proc. 1993. PMID: 8442094 No abstract available.
• Autologous graft-versus-host disease: a new frontier in immunotherapy.

  Hess AD, Jones RJ, Morris LE, Noga SJ, Yeager AM, Vogelsang GB, Santos GW. Hess AD, et al. Bone Marrow Transplant. 1992;10 Suppl 1:16-21. Bone Marrow Transplant. 1992. PMID: 1521086 Review. No abstract available.
• Autologous graft-vs-host disease: mechanisms and potential therapeutic effect.

  Hess AD, Jones RC, Santos GW. Hess AD, et al. Bone Marrow Transplant. 1993;12 Suppl 3:S65-9. Bone Marrow Transplant. 1993. PMID: 8124261 Review.
• Autologous graft-versus-host disease: a novel approach for antitumor immunotherapy.

  Hess AD, Jones RJ, Morris LE, Noga SJ, Vogelsang GB, Santos GW. Hess AD, et al. Hum Immunol. 1992 Jul;34(3):219-24. doi: 10.1016/0198-8859(92)90115-4. Hum Immunol. 1992. PMID: 1429045 Review.
• Syngeneic graft-versus-host disease after allogeneic bone marrow transplantation and cyclosporine treatment.

  Hess AD, Vogelsang GB, Silanskis M, Friedman KA, Beschorner WE, Santos GW. Hess AD, et al. Transplant Proc. 1988 Jun;20(3 Suppl 3):487-92. Transplant Proc. 1988. PMID: 3291285 No abstract available.